The Antibiotic Drought Of 2008: Plenty Of Action But No NME Approvals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The atypically small number of new molecular entity approvals from FDA's Office of Antimicrobial Products in 2008 belies the reviewers' full slate of NDAs, particularly of novel antibiotics
You may also be interested in...
UK Antibiotics Play Novacta Wins £13.1 million, mostly from Celtic Pharma
Funds should allow Novacta Biosystems to take three peptide-based ‘lantibiotics' programs through to proof-of-efficacy and secure a licensing deal
CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class
FDA’s second-half surge in approvals made 2008 the agency’s best year for NME approval counts since 2004, but the relatively high number is generated by a slate of products with a relatively low level of innovation.
CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class
FDA’s second-half surge in approvals made 2008 the agency’s best year for NME approval counts since 2004, but the relatively high number is generated by a slate of products with a relatively low level of innovation.